Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LXRX - Lexicon Pharmaceuticals Inc


IEX Last Trade
1.73
-0.070   -4.046%

Share volume: 3,307,233
Last Updated: Fri 30 Aug 2024 09:59:51 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.80
-0.07
-3.89%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
13%
Profitability 0%
Dept financing 11%
Liquidity 75%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
-5.46%
1 Month
-22.42%
3 Months
1.76%
6 Months
-33.72%
1 Year
-4.42%
2 Year
-35.93%
Key data
Stock price
$1.73
P/E Ratio 
-3.09
DAY RANGE
N/A - N/A
EPS 
-$0.77
52 WEEK RANGE
$0.92 - $3.73
52 WEEK CHANGE
$0.02
MARKET CAP 
625.382 M
YIELD 
N/A
SHARES OUTSTANDING 
361.492 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.98
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,562,412
AVERAGE 30 VOLUME 
$2,996,150
Company detail
CEO:
Region: US
Website: lexpharma.com
Employees: 304
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio

Recent news